EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2026 Interim Results at a glance

2026.08.05

H1 2026 Results Announcement: Regulatory Headwinds Drag Down, Revenue by 10.5% to HK$784.7 million and Profit by 32.2% to HK$110.7 million, Interim Dividend HK$0.05

2026.08.05

Essex Bio-Technology enters Strategic Collaboration Framework Agreement with Gunze Medical to further Commercial Access and to advance Research in Regenerative Medicine and Wound Care

2026.07.23

Date

Title

2019-07-19

Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea

2019-05-15

Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index

2019-04-29

Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting

2019-03-12

FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively

2019-01-10

The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award

2018-10-30

Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics

2018-10-29

Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018

2018-08-22

Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT